FDA approved the 7th CAR-T cell therapy Carvykti™
February 28, 2022, Carvykti™ (ciltacabtagene autoleucel), BCMA-directed CAR-T cell therapy, received U.S. FDA approval for the treatment of adult patients with relapsed or refractory multiple myeloma. Actually, evaluating BCMA CAR expression is an essential step in the manufacturing process of BCMA CAR-T cell therapy development. ACROBiosystems has developed high-quality BCMA proteins with FDA DMF filed for detecting anti-BCMA CARs in clinical trials, saving the time of preparing the filing of documents and supporting your IND or BLA.
